About 183,008 results

High Risk of Long COVID Neurologic Sequelae in Veterans
Jan Dyer

Oct 3rd, 2022 - We now know that the effects of COVID-19 don’t always end when the infection seems over. Long COVID—the postacute sequelae—can encompass a wide range of extrapulmonary organ dysfunctions.

Asthma Outcomes Improved With Use of Mindfulness-Based Stress Reduction
Pulmonology Advisor

Oct 3rd, 2022 - Training patients with asthma in mindfulness-based stress reduction (MBSR) improves clinically relevant outcomes and may therefore enhance asthma management, especially among those with comorbid psychopathology, according to study findings published in Brain, Behavior, and Immunity – Health. Asthma exacerbation risk is elevated in individuals with psychological distress and comorbid psychopatho...

Tocilizumab Normalizes Serum Amyloid Levels in Familial Mediterranean Fever
Rheumatology Advisor

Oct 3rd, 2022 - Tocilizumab vs placebo was found to normalize serum amyloid A (SAA) levels and decrease disease activity in patients with Familial Mediterranean Fever (FMF), according to findings published in the Journal of Clinical Medicine. FMF is an autoinflammatory disease that causes chronic inflammation without the presence of autoantibodies or antigen-specific T-lymphocytes. Symptoms include recurrent f...

Bupivacaine Now Available for Analgesia After Shoulder Surgery
Rheumatology Advisor

Oct 3rd, 2022 - Posimir® (bupivacaine solution) is now available for postsurgical analgesia for up to 72 hours following arthroscopic subacromial decompression. Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered into the subacromial space under direct arthroscopic visualization. The depot product uses a sucrose-based biodegradable matrix (sucrose acetate isobu...

Health Effects of Wildfires: Recent Research and What Clinicians Need to Know
Pulmonology Advisor

Sep 30th, 2022 - More than 1100 wildfires burned in the US during the month of September, according to the Fire, Weather, and Avalanche Center1 — a situation that, according to research, causes more people with asthma, other respiratory issues, and heart conditions to show up at doctors’ offices, emergency departments, and hospitals. The particulate matter generated by wildfires is especially hazardous for chil...

Long-Term Antibiotics Not Needed in CF Without Chronic P Aeruginosa
Pulmonology Advisor

Sep 30th, 2022 - Giving long-term inhaled antibiotics to people with cystic fibrosis (CF) who do not have chronic Pseudomonas aeruginosa (PA)infection does not improve outcomes, according to study findings published in Journal of Cystic Fibrosis. Practice guidelines recommend that people with CF receive chronic treatment with inhaled antibiotics if they are chronically infected with PA from the age of 6 years. ...

COVID-19 Vaccines Not Associated With Increased Risk for SLE Flares
Pulmonology Advisor

Sep 30th, 2022 - Vaccination against COVID-19 was not found to increase incidence of disease flares in patients with systemic lupus erythematosus (SLE) compared with those who were unvaccinated, according to study findings published in Vaccine. Researchers at the Department of Medicine at Tuen Mun Hospital in Hong Kong conducted a retrospective study to analyze patterns of vaccine hesitancy, vaccination status,...

Ezetimibe-statin combo lowers liver fat in open-label trial
Sara Freeman

Sep 30th, 2022 - Ezetimibe given in combination with rosuvastatin has a beneficial effect on liver fat in people with nonalcoholic fatty liver disease (NAFLD), according results of a randomized, active-controlled trial. The findings, which come from the investigator-initiated ESSENTIAL trial, are likely to add to the debate over whether or not the lipid-lowering combination could be of benefit beyond its effect.

Funding Substance Use Treatment via Medicaid Fee-For-Service May Increase Access
Endocrinology Advisor

Sep 30th, 2022 - Financing substance use services through Medicaid fee-for-service (FFS) may increase substance use disorder (SUD) treatment utilization in the United States, according to findings were published in JAMA Health Forum. Researchers at Boston University conducted a cross-sectional analysis and sourced data from the Treatment Episode Data Set-Admissions (TEDS-A) database and the Kaiser Family Founda...

ACC Recommendations on the Role of Nonstatin Therapies for Lowering LDL-C
Endocrinology Advisor

Sep 30th, 2022 - An expert consensus statement from the American College of Cardiology (ACC) on the role of nonstatin therapies for maintaining low-density lipoprotein cholesterol (LDL-C) levels to manage atherosclerotic cardiovascular disease (ASCVD) risk was published in the Journal of the American College of Cardiology. Newer nonstatin therapy options include ezetimibe, alirocumab or evolocumab, bempedoic ac...

Focus on Cardiometabolic Disease Risk in Psoriatic Arthritis – With Brittany Weber, MD
Rheumatology Advisor

Sep 30th, 2022 - Patients with vs without psoriatic arthritis (PsA) have markedly elevated risks to their cardiometabolic health. More than half of patients with PsA have at least 1 comorbidity (Figure 1).1 Patients with PsA are estimated to be 46% more likely to be diagnosed with a cardiovascular disease (CVD) than the general population, with a higher rate of hospitalization related to CVD as well.2 Moreover,...

Tecovirimat Shown to Alleviate Severe Proctitis in Patients With Monkeypox
Rheumatology Advisor

Sep 30th, 2022 - Tecovirimat is well tolerated and associated with the rapid alleviation of rectal pain among patients with severe proctitis secondary to monkeypox virus, according to case report findings published in Annals of Internal Medicine. In this case report, the study authors described the effects of oral tecovirimat for the treatment of monkeypox virus-associated severe proctitis in 2 men, both of who...

BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema

Sep 30th, 2022 - The oral Janus kinase (JAK) inhibitor baricitinib appears to improve symptoms of atopic dermatitis (AD) in children aged 2 years and up, as indicated by data from the phase 3 BREEZE-AD-PEDS trial. After 16 weeks of treatment, the primary endpoint ― an Investigators Global Assessment (IGA) score of 0 or 1 with at least a 2-point improvement from baseline ― was met by 41.7% of patients given 2 mg...

Hormones' Impact Described in Transgender Rheumatology Patients

Sep 30th, 2022 - Gender-affirming hormone therapy's effect on transgender patients with rheumatic disease is unclear but does not appear to modulate its course and does not need to be strictly contraindicated in most patients, according to a case series and systematic literature review. Dr Kristen Mathias More doctors are practicing transgender medicine, yet a limited amount of information is available on rheum...

Liver Fat Lowered by Ezetimibe-Statin Combination in Open-Label Trial

Sep 30th, 2022 - Ezetimibe given in combination with rosuvastatin has a beneficial effect on liver fat in people with nonalcoholic fatty liver disease (NAFLD), according results of a randomized, active-controlled trial. The findings, which come from the investigator-initiated ESSENTIAL trial, are likely to add to the debate over whether or not the lipid-lowering combination could be of benefit beyond its effect...

Image-Guided Superficial Radiation as First-line in Skin Cancer?

Sep 30th, 2022 - The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaway Absolute lesion control rate with image-guided superficial radiation therapy (IGSRT) for early-stage non-melanoma skin cancer was achieved in nearly all patients.  Why This Matters IGSRT is a newer radiation technique for skin cancer, an alternative to Mohs micrographic ...

52-Week Data Show Lebrikizumab Atopic Dermatitis Effects Maintained

Sep 30th, 2022 - Efficacy of the investigational drug lebrikizumab is maintained in patients with moderate to severe atopic dermatitis for at least 1 year, according to new results from the phase 3 ADvocate1 and ADvocate2 trials. "We're focused on the responders," said Andrew Blauvelt, MD, MBA, as he presented the positive findings at the European Academy of Dermatology and Venereology (EADV) 2022 Annual Meetin...

SMART-CHOICE 3-Year Results Support Dropping Aspirin After PCI

Sep 30th, 2022 - Shortening the duration of dual antiplatelet therapy (DAPT) and continuing with a P2Y12 inhibitor alone after percutaneous coronary intervention (PCI) was associated with a similar rate of ischemic events but with less bleeding than prolonged DAPT after 3 years of follow-up in the SMART-CHOICE trial. "The current results of extended follow-up from the SMART-CHOICE trial support evidence of an a...

Ketamine and Psilocybin Update in Treatment-Resistant Depression
Clinical Advisor

Sep 29th, 2022 - Highlights from Psych Congress 2022 include studies on the efficacy of psychedelics in patients with treatment-resistant depression. Two studies found that treatment with COMP360 psilocybin therapy reduced depression symptoms in patients with treatment-resistant depression, and a third study found that using precision medicine for ketamine dosing may decrease the high efficacy-low effectiveness...

Helmet May Be Better Than Facemask in CPAP for COVID-19 Respiratory Failure
Pulmonology Advisor

Sep 29th, 2022 - Continuous positive airway pressure (CPAP) delivered with a helmet interface, rather than a facemask, may prevent endotracheal intubation in patients with COVID-19 and moderate-to-severe respiratory failure, researchers reported in Chest. The prospective, single-center, cohort study compared clinical outcomes in patients with acute hypoxemic respiratory failure due to COVID-19 who received CPAP...